Search research articles
Contact Us
Filters
Showing results (51-60 of 114) with videos related to
Page
of 12
Sort By:
Future Oncology (London, England)
|
February 17, 2023
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Leukemia
|
September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Meletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
Leukemia & Lymphoma
|
April 5, 2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Ajai Chari, Sarah Larson, Beata Holkova, et al.
The Lancet. Oncology
|
November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Blood Advances
|
May 4, 2022
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
Ankit Kansagra, Angela Dispenzieri, Raphael Fraser, et al.
JCO Oncology Practice
|
October 17, 2024
Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas
Naveen Premnath, Yulun Liu, Heather Reves, et al.
Acta Medica Academica
|
June 16, 2023
SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation
Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, et al.
British Journal of Haematology
|
March 20, 2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Blood Cancer Journal
|
April 14, 2022
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Blood Cancer Journal
|
October 6, 2025
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
Laahn Foster, Larry D Anderson, Alfred Chung, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 114) with videos related to
Sort By:
Page
of 12
Future Oncology (London, England)
|
February 17, 2023
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Leukemia
|
September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Meletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
Leukemia & Lymphoma
|
April 5, 2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
Ajai Chari, Sarah Larson, Beata Holkova, et al.
The Lancet. Oncology
|
November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Blood Advances
|
May 4, 2022
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
Ankit Kansagra, Angela Dispenzieri, Raphael Fraser, et al.
JCO Oncology Practice
|
October 17, 2024
Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas
Naveen Premnath, Yulun Liu, Heather Reves, et al.
Acta Medica Academica
|
June 16, 2023
SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation
Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, et al.
British Journal of Haematology
|
March 20, 2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Blood Cancer Journal
|
April 14, 2022
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
Blood Cancer Journal
|
October 6, 2025
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
Laahn Foster, Larry D Anderson, Alfred Chung, et al.
Page
of 12